Dr. Streja is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7345 Medical Center Dr
Suite 600
West Hills, CA 91307Phone+1 818-347-2921Fax+1 818-346-4436
Education & Training
Carol Davila University of Medicine and PharmacyClass of 1961
Certifications & Licensure
CA State Medical License 1979 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
- Fellow (FACE) American Association of Clinical Endocrinology
Clinical Trials
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
- A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- Does the Benefit of Cholesterol-Lowering of a Given Magnitude Depend on the Drug Intervention Used?Elani Streja, Dan Streja
Circulation. Cardiovascular Quality and Outcomes. 2019-08-01 - 4 citationsPrecision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney DiseaseElani Streja, Dan Streja, Melissa Soohoo, Carola-Ellen Kleine, Jui-Ting Hsiung
Seminars in Nephrology. 2018-07-01 - The final word about LDL-cholesterol lowering.Dan Streja
Current Opinion in Endocrinology, Diabetes, and Obesity. 2018-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
